Cipla Ltd logo

Cipla Ltd

CIPLA NSE

Key Fundamentals

Volatility
Moderate
P/E Ratio
29.98
EBITDA
₹6,765 Cr
Return on Equity
15.5%
Debt to Equity
0.02
EPS
₹55.04
52W High
₹1,673
52W Low
₹1,165.7

Technical Indicators

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 25.7%

Weaknesses

2
  • The company has delivered a poor sales growth of 8.01% over past five years.
  • Promoter holding has decreased over last 3 years: -4.34%

Growth Rate

Revenue Growth
2.24% ↗
Net Income Growth
-26.86% ↘
Cash Flow Change
-21.28% ↘
ROE
-33.71% ↘
ROCE
-31.02% ↘
EBITDA Margin (Avg.)
-17.18% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 3d ago
AI opinion · based on fundamentals
Risk medium
HOLD Worth holding, not adding Conviction 5/10

Cipla trades at a PE of 28.4x with declining near-term profitability (TTM profit growth of -26%) but remains nearly debt-free with a solid long-term compounding track record of 11% profit CAGR over 10 years. The 59% buy rating from analysts suggests underlying confidence, but the recent earnings deterioration and muted 2% TTM sales growth warrant caution before fresh entry.

Bull Case 7
  • Company is almost debt-free, providing significant financial flexibility and resilience during industry downturns
  • 10-year compounded profit growth of 11% demonstrates consistent long-term earnings compounding ability
  • 59.46% of analysts (22 out of 37) rate the stock a Buy, reflecting majority institutional confidence
  • Healthy dividend payout ratio of 25.7% with current dividend yield of 0.96%, indicating shareholder-friendly capital allocation
  • 3-year ROE of 15% and 5-year ROE of 14% show sustained ability to generate returns above cost of equity
  • 10-year stock CAGR of 11% has delivered consistent wealth creation for long-term investors
  • Market cap of Rs 1,09,575 Cr positions Cipla as a large-cap with institutional liquidity and index inclusion benefits
Bear Case 8
  • TTM compounded profit growth has sharply declined to -26%, signaling significant near-term earnings pressure
  • TTM sales growth of just 2% indicates near-stagnation in revenue momentum
  • Promoter holding has decreased by 4.34% over last 3 years, raising concerns about insider confidence
  • 1-year stock CAGR of -10% shows the market has already been repricing the stock downward
  • PE of 28.4x is elevated relative to the earnings decline, suggesting limited margin of safety at current levels
  • 5-year compounded sales growth of only 8% is below pharma sector peers, reflecting market share challenges
  • Last year ROE dropped to 12% from 3-year average of 15%, indicating deteriorating capital efficiency
  • 16.22% of analysts (6 out of 37) have a Sell rating, a non-trivial bearish minority

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 1d ago
Positives 3
  • USFDA Goa facility clears VAI Jun 11

    USFDA classified Cipla's Goa manufacturing facility inspection as Voluntary Action Indicated, meaning no immediate regulatory action is required. This is a favorable outcome compared to the more stringent OAI classification.

  • New CEO for India Business Jun 16

    Cipla appointed Shivam Puri as CEO – One India Business effective July 1, 2026. The Board also granted him stock options and ESARs under employee benefit schemes.

  • ₹13 per share final dividend Jun 1

    Cipla convened its 90th AGM on June 25, 2026, with agenda items including a final dividend of ₹13 per equity share and appointment of new statutory auditors.

Neutral 4
  • Promoters report zero share encumbrance Jun 19

    Cipla promoters confirmed no shares were encumbered directly or indirectly during FY26, filed under SEBI takeover regulations.

  • ₹35.67 Cr block trade on NSE May 26

    Cipla recorded a block trade of ~2,51,702 shares at ₹1,417 per share valued at ₹35.67 crores, indicating significant institutional-level interest.

  • Investor meets at Citi & ICICI May 28

    Cipla scheduled analyst and institutional investor meetings at the Citi India Conference (June 5) and ICICI Securities India Investor Conference (June 9) in Mumbai.

  • ESG metrics filed for FY26 Jun 1

    Cipla filed its Business Responsibility and Sustainability Report for FY 2025-26, detailing ESG performance and governance disclosures.

TL;DR: Cipla is in a clean regulatory position with no headwinds — the USFDA's VAI classification for its Goa facility removes a key overhang and promoter encumbrance remains nil. Leadership continuity is strengthened with a dedicated India business CEO, and shareholder returns stay healthy with a ₹13/share dividend. Active institutional engagement and block trades suggest sustained investor interest. The near-term trend is stable-to-positive with no visible regulatory or operational risks emerging.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
5,739
6,329
6,678
6,604
6,163
6,694
7,051
7,073
6,730
6,957
7,589
7,074
6,541
Expenses
4,566
4,835
4,944
4,856
4,847
4,978
5,165
5,084
5,192
5,179
5,695
5,819
5,586
Operating Profit
1,174
1,494
1,734
1,748
1,316
1,716
1,886
1,989
1,538
1,778
1,895
1,255
955
OPM %
20%
24%
26%
26%
21%
26%
27%
28%
23%
26%
25%
18%
15%
Other Income
-48
136
176
-10
249
160
191
222
289
259
269
-70
148
Interest
34
16
26
30
18
18
15
15
14
14
13
14
13
Depreciation
346
239
290
233
288
247
272
280
309
253
297
278
383
PBT
745
1,375
1,594
1,474
1,259
1,611
1,789
1,916
1,504
1,770
1,854
893
707
Tax %
30%
28%
28%
28%
26%
27%
27%
17%
19%
27%
27%
24%
22%
Net Profit
522
998
1,155
1,068
932
1,175
1,305
1,575
1,214
1,292
1,353
674
543
EPS in Rs
6.51
12.33
14.01
13.08
11.63
14.58
16.13
19.45
15.13
16.06
16.73
8.37
6.87
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
11,345
13,790
14,394
15,156
16,362
17,132
19,160
21,763
22,753
25,774
27,548
28,163
Expenses
9,183
11,310
11,898
12,329
13,265
13,926
14,907
17,211
17,726
19,483
20,420
22,280
Operating Profit
2,163
2,480
2,496
2,826
3,097
3,206
4,252
4,553
5,027
6,291
7,128
5,883
OPM %
19%
18%
17%
19%
19%
19%
22%
21%
22%
24%
26%
21%
Other Income
164
208
208
280
477
344
266
99
293
552
862
606
Interest
168
207
159
114
168
197
161
106
110
90
62
54
Depreciation
505
754
1,323
1,323
1,326
1,175
1,068
1,052
1,172
1,051
1,107
1,211
PBT
1,654
1,727
1,222
1,669
2,079
2,178
3,290
3,493
4,038
5,702
6,821
5,224
Tax %
24%
19%
15%
15%
27%
29%
27%
27%
30%
27%
22%
26%
Net Profit
1,229
1,383
1,035
1,417
1,492
1,500
2,389
2,547
2,833
4,154
5,269
3,862
EPS in Rs
14.71
16.93
12.51
17.52
18.96
19.18
29.82
31.19
34.71
51.05
65.28
48.02
Div. Payout %
14%
12%
16%
17%
16%
21%
17%
16%
24%
25%
25%
27%
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
161
161
161
161
161
161
161
161
161
161
162
162
Reserves
10,641
11,356
12,383
14,068
14,851
15,602
18,165
20,680
23,246
26,545
31,032
34,270
Borrowings
1,703
5,202
4,113
4,098
4,316
2,816
2,014
1,056
803
559
438
614
Other Liabilities
3,166
4,331
4,213
4,346
4,433
4,843
4,514
4,960
5,089
5,267
5,702
7,297
Total Liabilities
15,670
21,049
20,869
22,673
23,762
23,423
24,855
26,857
29,300
32,533
37,334
42,343
Fixed Assets
6,830
9,368
9,492
9,950
9,608
9,683
9,516
9,683
9,160
9,607
10,006
12,434
CWIP
581
2,061
1,683
981
676
825
969
766
1,093
1,153
1,566
2,042
Investments
640
759
973
1,259
2,554
1,471
2,710
2,551
3,662
5,449
7,933
8,223
Other Assets
7,620
8,862
8,721
10,483
10,923
11,444
11,661
13,857
15,384
16,323
17,828
19,643
Total Assets
15,670
21,049
20,869
22,673
23,762
23,423
24,855
26,857
29,300
32,533
37,334
42,343
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
1,173
1,741
2,382
1,463
1,691
3,068
3,755
3,326
3,238
4,134
5,005
3,940
Investing
-950
-4,533
-1,304
-834
-1,688
114
-2,374
-1,858
-2,376
-2,982
-3,682
-2,234
Financing
165
3,104
-1,326
-385
-349
-2,949
-1,240
-1,600
-958
-1,200
-1,293
-1,234
Net Cash Flow
388
312
-248
243
-345
234
141
-132
-97
-49
30
473
Free Cash Flow
548
688
1,284
723
1,187
2,083
2,964
2,645
2,102
2,819
3,490
928
CFO/OP
72
91
113
77
74
122
113
98
90
91
94
94
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
64
62
65
75
93
83
66
57
65
68
73
73
Inventory Days
329
273
239
271
250
267
232
230
228
217
231
252
Days Payable
126
106
108
142
123
139
103
108
112
102
116
123
Cash Conversion Cycle
267
230
196
204
220
211
195
180
181
182
188
202
Working Capital Days
89
-10
99
118
132
113
94
95
113
120
128
106
ROCE %
15%
13%
7%
9%
11%
12%
17%
17%
18%
23%
23%
15%

Shareholding Pattern

As of Mar 2026
DIIs 31.71%
Promoters 29.22%
FIIs 22.55%
Public 16.26%
Government 0.27%
Total 100.01%
  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters
33.46%
33.46%
33.46%
33.46%
30.91%
30.93%
29.19%
29.20%
29.19%
29.22%
29.22%
29.22%
FIIs
25.49%
25.74%
25.73%
25.82%
27.82%
28.80%
26.65%
26.28%
25.24%
24.54%
23.93%
22.55%
DIIs
24.05%
23.90%
24.05%
24.15%
24.66%
23.95%
27.49%
27.89%
28.98%
29.98%
30.45%
31.71%
Government
0.21%
0.21%
0.21%
0.21%
0.21%
0.21%
0.23%
0.26%
0.27%
0.27%
0.27%
0.27%
Public
16.76%
16.68%
16.53%
16.36%
16.40%
16.11%
16.43%
16.36%
16.30%
15.99%
16.12%
16.26%
No. of Shareholders
4,66,515
4,26,863
4,25,731
4,36,154
4,63,569
4,70,234
5,25,114
5,43,420
5,49,655
5,34,587
5,40,521
5,84,217

Documents

1
Concall - May 2017 May 2017
2
Concall - May 2017 May 2017
3
Concall - Aug 2017 Aug 2017
4
Concall - Nov 2017 Nov 2017
5
Concall - Feb 2018 Feb 2018

Frequently Asked Questions about Cipla Ltd

What does Cipla Ltd do?
Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs[1]
Where is Cipla Ltd (CIPLA) listed?
Cipla Ltd is listed on the Indian stock exchanges. It is listed on NSE: CIPLA and BSE: 500087. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Cipla Ltd belong to?
Cipla Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the PE ratio of Cipla Ltd?
The Price-to-Earnings (PE) ratio of Cipla Ltd is 29.98. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Cipla Ltd?
Over the past 52 weeks, Cipla Ltd has traded between a low of ₹1,165.7 and a high of ₹1,673. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Cipla Ltd?
Cipla Ltd has a Return on Equity (ROE) of 15.50%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Cipla Ltd on Tapetide?
On Tapetide, you can view Cipla Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs[1]

Website cipla.com
CEO Mr. Umang Vohra B.E., M.B.A.
Employees 30,313
Listed 1995-02-08
Face Value ₹ 2
Issued Size 80,77,71,798

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List